Biotech CEO sentenced for $28M fraud scheme

The CEO of biotech company Decision Diagnostics Corp., Keith Berman, was sentenced to seven years in prison for a securities fraud scheme that resulted in about $28 million in investor losses and obstruction of a related U.S. Securities and Exchange Commission investigation.

Advertisement

From February through December 2020, Mr. Berman falsely claimed that Decision Diagnostics created a 15-second test to detect COVID-19 in a finger prick sample of blood. Though the test did not exist, he told investors that the FDA was on the brink of approving it. Mr. Berman also obstructed an SEC investigation into his conduct.

Mr. Berman pleaded guilty to securities fraud, wire fraud and obstruction of an official proceeding.

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.